Key Dates

Related Announcements

•  February 2, 2024 - Notice of Special Interest (NOSI): RNA Delivery Technologies to Allow Specific Tissue Target Homing (RNA-DASH). See Notice NOT-AI-24-007.

Issued by

National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

This Notice announces the participation of the National Institute of Neurological Disorders and Stroke (NINDS) in NOT-AI-24-007 "Notice of Special Interest (NOSI): RNA Delivery Technologies to Allow Specific Tissue Target Homing (RNA-DASH)," effective May 12, 2024.

Changes to the NOSI are shown below:

Currently Reads:

Issued By

National Institute of Allergy and Infectious Diseases (NIAID)

National Center for Advancing Translational Sciences (NCATS)

National Cancer Institute (NCI)

Purpose

Research Topics of Interest

NCATS

Delivery of RNA therapeutics and/or genome editors for the treatment of rare diseases; broad spectrum delivery technologies for RNA therapeutics and/or genome editors that go to multiple tissues; technologies to target RNA therapeutics and/or genome editors to specific cells and tissues; delivery technologies based on phages.
 

Modified to Read:

Issued By

National Institute of Allergy and Infectious Diseases (NIAID)

National Center for Advancing Translational Sciences (NCATS)

National Cancer Institute (NCI)

National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

Research Topics of Interest

NCATS

Delivery of RNA therapeutics and/or genome editors for the treatment of rare diseases; broad spectrum delivery technologies for RNA therapeutics and/or genome editors that go to multiple tissues; technologies to target RNA therapeutics and/or genome editors to specific cells and tissues; delivery technologies based on phages.

National Institute of Neurological Disorders and Stroke (NINDS)

The National Institute for Neurological Disorders and Stroke (NINDS) is interested in applications to NOT-AI-24-007 that fall within the NINDS mission space. Particular areas of interest include:

• Delivery methods and strategies that enable transport of RNA-based therapeutics across the blood-brain barrier
• Delivery methods and strategies that target RNA-based therapeutics to specific regions of the peripheral and/or central nervous system
• Delivery methods and strategies that target RNA-based therapeutics to specific cell populations of the peripheral and/or central nervous system
• Strategies for sustained expression and/or activity of RNA-based therapeutics targeted to cells of the peripheral and/or central nervous system

NINDS may decline funding of any application for programmatic or administrative reasons. Potential applicants are strongly encouraged to contact program staff early in the process of preparing a submission. To learn more about the NINDS Small Business Program please visit https://www.ninds.nih.gov/funding/ninds-small-business-program.

Part 2. Section VII. Agency Contacts

Scientific/Research Contact(s)

Emily Caporello, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Phone: 301-496-1778
Email: emily.caporello@nih.gov

Financial/Grants Management Contact(s)

Chief Grants Management Officer
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-9231
Email: ChiefGrantsManagementOfficer@ninds.nih.gov

All other aspects of this Notice remain the same.

Inquiries

Please direct all inquiries to:

Emily Caporello, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Phone: 301-496-1778
Email: emily.caporello@nih.gov